Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of September 11, 2026, ACAD trades at $28.07 with a market cap of $4.78B and a P/E ratio of 12.39. ACAD moved +0.34% today. Year to date, ACAD is +5.86%; over the trailing twelve months it is +15.00%. Its 52-week range spans $13.40 to $30.96. Analyst consensus is strong buy with an average price target of $35.47. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ACAD combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $28.07 |
| Market Cap | $4.78B |
| P/E Ratio | 12.39 |
| EPS | $2.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.96 |
| 52-Week Low | $13.40 |
| Volume | 920.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.14B |
| Net Income | $380.48M |
| Gross Margin | 91.13% |
16 analysts cover ACAD: 0 strong buy, 12 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.47.